Tests modafinil for thinking problems in multiple sclerosis

Trial details

Who runs it

Clinical Academic Center (2CA-Braga)

Trial code

NCT06592352EU 2022-501414-53-00

Record updated

13 August 2025

Original description

This is a phase II/exploratory clinical trial with a single-center, open-label design to evaluate the effect of modafinil on cognitive deficits in adult patients with multiple sclerosis and identify predictors of response using functional Magnetic Resonance Imaging (fMRI).Read full original descriptionShow less

MODAFIMS: An Open-label, Single-center Clinical Trial to Evaluate Predictors of Response to MODAFinil in the Treatment of Cognitive Deficits in Patients With Multiple Sclerosis

This is a phase II/exploratory clinical trial with a single-center, open-label design to evaluate the effect of modafinil on cognitive deficits in adult patients with multiple sclerosis and identify predictors of response using functional Magnetic Resonance Imaging (fMRI).

Inclusion: Participant is willing and able to give informed consent for the participation in the trial; Patients that are able to read and write; Male or female, aged between 18 and 64 years old at the time of signing the ICF; Diagnosed with Relapsing-Remitting MS or Clinically Isolated Syndrome, according to McDonald 2017 diagnostic criteria (Thompson et al., 2018); Expanded disability status score (EDSS) less than 6.5; Presence of subjective cognitive complaints; SDMT score (number of correct responses within 90 seconds) at Screening ≤ 55 (Benedict et al., 2016; Parmenter et al., 2007); Female participants of childbearing potential and male participants whose partner is of childbearing potential must be willing to ensure that they or their partner use protocol's recommended effective contraception methods, which is not based only on hormonal methods, during all the 6 months of the trial (3 months of treatment plus 3 months of safety follow-up); Male participants must agree to refrain from donation of semen from first study treatment administration up to at least 90 days after last administration; Participants, that in the medical investigator's opinion, are able and willing to comply with all trial requirements.

Exclusion: Participants who have participated in another research trial involving an investigational product within the past 5 half-lives of the other investigational product; Participants with a history of left ventricular hypertrophy or cor pulmonale and patients with mitral valve prolapse who developed mitral valve prolapse syndrome when previously treated with central nervous system stimulants; A documented history of attempted suicide in the last 2 years OR suicidal ideation with intent, with or without a plan or method (e.g., positive response to items 4 or 5 in the assessment of suicidal ideation on the C-SSRS) over the 6 months prior to the Screening Visit; Participants taking warfarin or any other prohibited medication; Participants who have any contra-indication for taking modafinil, according to the prescribing information and SmPC, such as hypersensitivity to the active substance and any excipient present in the modafinil or any documented adverse reaction after modafinil intake; Significant neurological history aside from MS (e.g., Epilepsy); Significant psychiatric history (e.g., Schizophrenia, Bipolar Disorder, Major Depression, severe anxiety disorder, aggressive or hostile behaviour); History of severe hypersensitivity reactions to any medicine; Known immunodeficiency syndrome; Positive test for anti-Human Immunodeficiency virus 1 or 2 antibodies, Hepatitis B surface antigen (HBsAg) or anti Hepatitis C virus antibodies; History of alcoholism or drug abuse; Participants with increased risk of epileptic seizures, history of cardiac arrhythmias, or uncontrolled moderate to severe hypertension; Sleep complaints confirmed by Epworth Sleepiness Scale (ESS) scale score \>10 at screening visit OR known sleep disorder; Any other condition that, in the opinion of the investigator, contra-indicates the participation of the patient; Participants with known hereditary galactose intolerance, total lactase deficiency or glucose-galactose malabsorption; Have serum alanine aminotransferase (ALT) values greater than 3 times the upper limit of normal at screening; Creatinine clearance \< 20 ml/min determined by Cockcroft-Gault equation; Female participant who is pregnant, breastfeeding or planning pregnancy during the trial; Participants who have any disability that, in the opinion of the investigator, significantly interferes with the neuropsychological testing and/or the tasks in the functional MRI; Participants not able to undergo MRI scanning; Current use of modafinil, armodafinil; Current use of other psychostimulants, including amphetamines, cocaine, bupropion, gingko biloba, among others, and beverages or food containing methylxanthines (e.g., coffee, tea, cola, caffeine, chocolate, sodas) exceeding 500 mg methylxanthines per day (for example, consumption of more than 5 espresso coffees or 100 mg of dark chocolate per day; Sanchez, 2017); Significant insomnia (grade \> 1 according to Common Terminology Criteria for Adverse Events, CTCAE v5); Presence of any clinically significant abnormality in ECG morphology or ECG parameters; Average daily consumption of more than 20 cigarettes; Participants with disability that interferes with the performance of the CT procedures (for example, motor deficit in upper limb, decreased visual acuity even with correction).

ClinicalTrials.gov NCT06592352 · EU CTIS 2022-501414-53-00